Mitch A. Phelps

Mitch A. Phelps, PhD

Director of the Pharmacoanalytical Shared Resource, OSU Comprehensive Cancer Center
B.A. in Physics, Ohio Wesleyan University
M.A. in Business Management, Labor and Human Resources, The Ohio State University
Ph.D in Biophysics, The Ohio State University

Mitch A. Phelps, PhD is Director of the OSU Comprehensive Cancer Center Pharmacoanalytical Shared Resource, which supports pharmacokinetic (PK)/pharmacodynamic (PD) study design and conduct for pre-clinical and clinical drug development. Dr. Phelps has directed PK/PD studies in preclinical disease models and in early phase clinical trials for nearly ten years.  His research group focuses on development of small molecule and oligonucleotide anticancer and immune-modulatory agents here at OSU, using statistical modeling and simulation of PK/PD data to understand how genetic and other factors contribute to differences in therapy outcomes among individuals.  Dr. Phelps is an associate professor in the College of Pharmacy Division of Pharmaceutics and Pharmaceutical Chemistry and in the College of Medicine Department of Pharmacology.

Research Interests

Preclinical Disease

Early Phase Clinical Trials

Development of Small Molecule and Oligonucleotide Anticancer and Immune Agents

Honors

  • 2005 Outstanding Graduate Student Award.
  • 2003-2004 Predoctoral Fellowship.
  • 2004 Predoctoral Fellowship.
  • 2003 Ray Travel Award.
  • 2001 Hazel Brown Teaching Award.

Journal Articles

2017

  • Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA, 2017, "Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial." Clin Pharmacol Ther ePub ahead of print, ePub - ePub.

2016

  • Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd, 2016, "NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines." Cancer Immunol Res 4, no. 4, 323-36 - 323-36.
  • Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F, 2016, "Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers." J Proteomics 136, 89-98 - 89-98.
  • Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK, 2016, "Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents." AAPS J 18, no. 3, 737-45 - 737-45.
  • Mani R, Yan R, Mo X, Chen CS, Phelps MA, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N, 2016, "Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma." Vet Comp Oncol ePub ahead of print, ePub - ePub.
  • Phelps M, Coss C, Wang H, Cook M, 2016, "Reproducibility Project: Cancer Biology; Reproducibility Project Cancer Biology. Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs." Elife 5, e12470 - e12470.

2015

  • Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, 2015, "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma." Br J Haematol 169, no. 5, 701-10 - 701-10.
  • Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ, 2015, "OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells." Blood 125, no. 2, 284-95 - 284-95.
  • Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N, 2015, "ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo." Exp Hematol 43, no. 9, 770-4 - 770-4.
  • Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA., 2015, "Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma." Leuk Lymphoma 56, no. 10, 2834-40 - 2834-40.
  • Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA, 2015, "Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)." Am J Hematol 90, no. 4, 327-33 - 327-33.
  • Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R, 2015, "Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia." Blood 125, no. 17, 2689-92 - 2689-92.
  • Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, 2015, "Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia." Leukemia 29, no. 2, 346-55 - 346-55.

2014

  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC, 2014, "Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma." Am J Hematol 89, no. 1, 19-24 - 19-24.
  • Kitzmiller JP, Phelps MA, Neidecker MV, Apseloff G, 2014, "Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly accredited interdisciplinary training program at the Ohio State University." Adv Med Educ Pract 5, 191-6 - 191-6.
  • Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA, 2014, "A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia." Leuk Res 38, no. 9, 1025-9 - 1025-9.
  • Hosoya K, Couto CG, London CA, Kisseberth WC, Phelps MA, Dalton JT, 2014, "Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors." J Am Anim Hosp Assoc 50, no. 6, 390-5 - 390-5.
  • Wang J, Luzum JA, Phelps MA, Kitzmiller JP, 2014, "Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma." J Chromatogr B Analyt Technol Biomed Life Sci 983-4, 18-25 - 18-25.
  • Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski, MA, Villalona-Calero MA, 2014, "Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses." Clin Pharmacol Ther 96, no. 2, 182-91 - 182-91.
  • Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC, 2014, "A phase I trial of flavopiridol in relapsed multiple myeloma." Cancer Chemother Pharmacol 73, no. 2, 249-57 - 249-57.

2013

  • Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, Phelps M, Martin EW Jr, Tweedle MF, 2013, "Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice." Bioconjug Chem 24, no. 11, 1945-54 - 1945-54.
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM, 2013, "Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia." Leukemia Research 37, no. 10, 1195-9 - 1195-9.
  • Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W, 2013, "Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia." Leukemia and Lymphoma E-pub ahead of print, 01 - 01.
  • Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA, 2013, "A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol." CLINICAL CANCER RESEARCH 19, no. 5, 1269-1280 - 1269-1280.
  • Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MA, 2013, "Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.." J Pharm Biomed Anal 88, no. 25, 262-8 - 262-8.
  • Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA, 2013, "Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.." Clinical Pharmacokinetics 52, no. 8, 705-12 - 705-12.
  • Mao,Yicheng; Triantafillou,Georgia; Hertlein,Erin; Towns,William; Stefanovski,Matthew; Mo,Xiaokui; Jarjoura,David; Phelps,Mitch; Marcucci,Guido; Lee,Ly,James; Goldenberg,David,M; Lee,Robert,J; Byrd,John,C; Muthusamy,Natarajan, 2013, "Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74(+) B-cell Malignancies." CLINICAL CANCER RESEARCH 19, no. 2, 347-356 - 347-356.
  • Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T, 2013, "A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors." Investigational New Drugs 31, no. 3, 685-695 - 685-695.

2012

  • Dulin JA, Drost WT, Phelps MA, Santschi EM, Menendez MI, Bertone AL, 2012, "Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses." Am J Vet Res 73, no. 3, 418-25 - 418-25.
  • He L, Grecula JC, Ling Y, Enzerra MD, Ammirati M, Kendra K, Cavaliere R, Mayr N, McGregor J, Olencki T, Mrozek E, Matharbootham M, Oluigbo C, Phelps MA, 2012, "Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue." JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 905, 141-144 - 141-144.
  • Rozewski DM, Herman SE, Towns WH 2nd, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D, Byrd JC, Johnson AJ, Phelps MA, 2012, "Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice." AAPS JOURNAL 14, no. 4, 872-882 - 872-882.
  • Hofmeister,Craig,C; Yang,Xiaoxia; Phelps,Mitch,A, 2012, "Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein Reply." JOURNAL OF CLINICAL ONCOLOGY 30, no. 3, 341-342 - 341-342.
  • Kitzmiller JP, Embi PJ, Manickam K, Sweet KM, Phelps MA, Jackson RD, Marsh CB, Sadee W, 2012, "Program in Pharmacogenomics at the Ohio State University Medical Center." PHARMACOGENOMICS 13, no. 7, 751-756 - 751-756.
  • Bill MA, Nicholas C, Mace TA, Etter JP, Li C, Schwartz EB, Fuchs JR, Young GS, Lin L, Lin J, He L, Phelps M, Li PK, Lesinski GB, 2012, "Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines." PLOS ONE 7, no. 8, e40724 - e40724.
  • Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC, 2012, "Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 97, no. 3, 423-427 - 423-427.

2011

  • Bekaii-Saab T*; Phelps MA*; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA, 2011, "Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology 29, no. 17, 2357-2363 - 2357-2363.
  • Kitzmiller JP, Groen DK, Phelps MA, Sadee W, 2011, "Pharmacogenomic Testing: Relevance in Medical Practice." Cleveland Clinic Journal of Medicine 78, no. 4, 243-257 - 243-257.
  • Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen CS, Farag SS, Grever MR, Byrd JC, Phelps MA, 2011, "Phase I Trial of Lenalidomide and CCI‐779 in Patients with Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein." Journal of Clinical Oncology 29, no. 25, 3427-3434 - 3427-3434.
  • Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Pan L, Chan KK, Kinghorn AD, Phelps MA, Grever MR, Lucas DM, 2011, "Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells." AAPS Journal 13, no. 3, 357-364 - 357-364.
  • Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC, 2011, "Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol." Leukemia 25, no. 9, 1444-1451 - 1444-1451.
  • Andritsos L, Jaglowski S, Stark A, Lin T, Jones J, Heerema N, Blum K, Flynn J, Moran M, Mitchell S, Lozanski G, Johnson A, Mahoney E, Phelps M, Byrd J, Grever M, 2011, "Low incidence of opportunistic infections with single agent flavopiridol for treatment of chronic lymphocytic leukemia." Blood
  • Saradhi UV*, Gupta SV*, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas DM, Grever MR, Phelps MA**, Chan KK**, 2011, "Characterization of silvestrol pharmacokinetics in mice using liquid chromatography–tandem mass spectrometry." AAPS Journal 13, no. 3, 347-356 - 347-356.

2010

  • Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, Phelps MA, 2010, "Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.." Plos One 5, no. 11, e13792 - e13792.
  • Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC, 2010, "Dose escalation of lenalidomide in relapsed or refractory acute leukemias.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology 28, no. 33, 4919-4925 - 4919-4925.
  • Riesen SC, Ni W, Carnes CA, Lindsey KJ, Phelps MA, Schober KE, 2010, "Pharmacokinetics of oral ivabradine in cats." Journal of Veterinary Pharmacology and Therapeutics 34, no. 5, 469-475 - 469-475.
  • Blum W*; Phelps MA*; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR, 2010, "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.." Haematologica 95, no. 7, 1098-1105 - 1098-1105.
  • Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai J, Wolfson A, Lustberg M, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, and Shah MH, 2010, "A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors." Investigational New Drugs 30, no. 2, 629-638 - 629-638.

2009

  • Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC, 2009, "Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology 27, no. 35, 6012-6018 - 6012-6018.
  • Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC, 2009, "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.." Leukemia & Lymphoma 50, no. 12, 1958-1963 - 1958-1963.
  • Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT, 2009, "Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.." Blood 113, no. 12, 2637-2645 - 2637-2645.
  • Yang X; Zhao X; Phelps MA; Piao L; Rozewski DM; Liu Q; Lee LJ; Marcucci G; Grever MR; Byrd JC; Dalton JT; Lee RJ, 2009, "A novel liposomal formulation of flavopiridol.." International Journal Of Pharmaceutics 365, no. 1-2, 170-174 - 170-174.
  • Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ, 2009, "A novel liposomal formulation of." Int J Pharm 365, no. 1-2, 170-4 - 170-4.

2008

  • Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA, 2008, "Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.." Therapeutic Drug Monitoring 30, no. 5, 620 - 620.
  • Phelps,Mitch,A; Rozewski,Darlene,M; Johnston,Jeffrey,S; Farley,Katherine,L; Albanese,Katie,A; Byrd,John,C; Lin,Thomas,S; Grever,Michael,R; Dalton,James,T, 2008, "Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule." JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 868, no. 1-2, 110-115 - 110-115.
  • Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, Dalton JT., 2008, "Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.." Journal Of Chromatography. B, Analytical Technologies In The Biomedical And Life Sciences 871, no. 1, 15-21 - 15-21.

2007

  • Byrd,John,C; Lin,Thomas,S; Dalton,James,T; Wu,Di; Phelps,Mitch,A; Fischer,Beth; Moran,Mollie; Blum,Kristie,A; Rovin,Brad; Brooker-McEldowney,Michelle; Broering,Sarah; Schaaf,Larry,J; Johnson,Amy,J; Lucas,David,M; Heerema,Nyla,A; Lozanski,Gerard; Young,Donn,C; Suarez,Jose-Ramon; Colevas,A,Dimitrios; Grever,Michael,R, 2007, "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia." Blood 109, no. 2, 399-404 - 399-404.
  • Christian BA, Fischer B, Blum KA, Brooker-McEldowney M, Moran ME, Andritsos LA, Phelps MA, Dalton JT, Colevas AD, Byrd JC, Grever MR, Lin TS, 2007, "Flavopiridol in Chronic Lymphocytic Leukemia." Clinical Leukemia 5, no. 1, 292-297 - 292-297.

2005

  • Gao,W,Q; Reiser,P,J; Coss,C,C; Phelps,M,A; Kearbey,J,D; Miller,D,D; Dalton,J,T, 2005, "Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats." Endocrinology 146, no. 11, 4887-4897 - 4887-4897.

Unknown

  • Peter Y. Yu, Heather L. Gardner, Ryan Roberts, Hakan Cam, Seethalakshmi Hariharan, Ling Ren, Amy K. LeBlanc, Jiayuh Lin, Denis C. Guttridge, Xiaokui Mo, Mitch A. Phelps, Peter Houghton, Cheryl A. London, "Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5." PlosONE

Associated Programs

Master of Science in Translational Pharmacology